These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22771009)

  • 41. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
    Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
    J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
    Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
    Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
    Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.
    Liu K; Rao W; Parikh H; Li Q; Guo TL; Grant S; Kellogg GE; Zhang S
    Eur J Med Chem; 2012 Jan; 47(1):125-37. PubMed ID: 22074985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
    Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-based discovery of cellular-active allosteric inhibitors of FAK.
    Tomita N; Hayashi Y; Suzuki S; Oomori Y; Aramaki Y; Matsushita Y; Iwatani M; Iwata H; Okabe A; Awazu Y; Isono O; Skene RJ; Hosfield DJ; Miki H; Kawamoto T; Hori A; Baba A
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1779-85. PubMed ID: 23414845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.
    Isshiki Y; Kohchi Y; Iikura H; Matsubara Y; Asoh K; Murata T; Kohchi M; Mizuguchi E; Tsujii S; Hattori K; Miura T; Yoshimura Y; Aida S; Miwa M; Saitoh R; Murao N; Okabe H; Belunis C; Janson C; Lukacs C; Schück V; Shimma N
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1795-801. PubMed ID: 21316218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma.
    Fuchikami K; Togame H; Sagara A; Satoh T; Gantner F; Bacon KB; Reinemer P
    J Biomol Screen; 2002 Oct; 7(5):441-50. PubMed ID: 14599360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening.
    Choi H; Lee Y; Park H; Oh DS
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6195-8. PubMed ID: 20850306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
    Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
    Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
    Park H; Kim S; Kim YE; Lim SJ
    ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovering new PI3Kα inhibitors with a strategy of combining ligand-based and structure-based virtual screening.
    Yu M; Gu Q; Xu J
    J Comput Aided Mol Des; 2018 Feb; 32(2):347-361. PubMed ID: 29306979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
    Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
    J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selectivity of kinase inhibitor fragments.
    Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
    J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
    Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
    J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
    Park H; Lee S; Hong S
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.
    Zhang H; Xin MH; Xie XX; Mao S; Zuo SJ; Lu SM; Zhang SQ
    Bioorg Med Chem; 2015 Dec; 23(24):7765-76. PubMed ID: 26652969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
    Finlay MR; Buttar D; Critchlow SE; Dishington AP; Fillery SM; Fisher E; Glossop SC; Graham MA; Johnson T; Lamont GM; Mutton S; Perkins P; Pike KG; Slater AM
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4163-8. PubMed ID: 22607682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.